Altimmune (ALT) vs Turn Therapeutics (TTRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Turn Therapeutics (TTRX) has outperformed Altimmune (ALT) over the past year, gaining 147.6% versus a loss of 72.3%. Altimmune is the larger company by market cap ($258.8 million vs $247.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALT | TTRX |
|---|---|---|
| Share price | $1.33 | $8.10 |
| Market cap | $258.80M | $247.49M |
| 1-day change | -5.67% | -6.31% |
| YTD return | -63.16% | +105.46% |
| 1-year return | -72.35% | +147.55% |
| 5-year return | -87.24% | — |
| EPS (TTM) | $-0.71 | $-0.43 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $41.00K | — |
| Revenue growth (YoY) | +105.00% | — |
| Net income (latest FY) | $-88.09M | $-3.19M |
| Operating margin | -230460.98% | — |
| Net margin | -214860.98% | — |
| 52-week high | $6.44 | $16.45 |
| 52-week low | $1.32 | $2.70 |
| Distance from 52-week high | -79.35% | -50.79% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +1127.82% | +208.83% |
| Average volume | 3.91M | 119.32K |
| Shares outstanding | 194.59M | 30.57M |
| Employees | 57 | 2 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TTRX has outperformed ALT by 219.9 percentage points over the past year.
About Altimmune
ALT stock →Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 57 employees
About Turn Therapeutics
TTRX stock →Turn Therapeutics Inc., operates as a pharmaceuticals company that develops drugs to treat diseases of the skin, nails, and eye. The company's delivery technology penetrates the skin and nails and reduces antibiotic through acute and chronic wound care products, enabling healthcare institutions to care for a variety of skin conditions, ranging from acute to chronic wounds, skin conditions, and dermatoses.
Health Care · Biotechnology: Pharmaceutical Preparations · 2 employees
ALT vs TTRX FAQ
Which is bigger, Altimmune or Turn Therapeutics?
Altimmune (ALT) is larger, with a market capitalization of $258.80M compared with $247.49M for Turn Therapeutics (TTRX).
Which stock has performed better over the past year, ALT or TTRX?
TTRX returned +147.55% over the past 12 months, compared with -72.35% for ALT (price return, excluding dividends). Past performance does not predict future results.
Are Altimmune and Turn Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.